Article
Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.
Human molecular genetics - 9 Feb 2026
Thorolfsdottir Rosa B, Sveinbjornsson Gardar, Hjorleifsson Eldjarn Grimur, Aegisdottir Hildur M, Styrkarsdottir Unnur, Gretarsdottir Solveig, Steinthorsdottir Valgerdur, Tragante Vinicius, Oddsson Asmundur, Stefansdottir Lilja, Thorleifsson Gudmar, Einarsson Gudmundur, Helgason Hannes, Jonsdottir Andrea B, Gudjonsson Sigurjon A, Ferkingstad Egil, Brunak Søren, Brøns Nanna, Bundgaard Johan S, Bruun Mie T, Erikstrup Christian, Aagaard Bitten, Vesterager Pedersen Ole B, Sibilitz Kirstine L, Sørensen Erik, Træholt Jacob, Ullum Henrik, Zheng Chaoqun, Knowlton Kirk U, Nadauld Lincoln D, Ostrowski Sisse R, Bundgaard Henning, Arnar David O, Jonsdottir Ingileif, Helgadottir Anna, Thorsteinsdottir Unnur, Holm Hilma, Sulem Patrick, Gudbjartsson Daniel F, Stefansson Kari
Abstract excerpt
The causal effect of lower plasma sclerostin on cardiovascular disease (CVD) risk has previously been examined with the aim of investigating potential side effects of pharmacological sclerostin inhibition for treatment of osteoporosis. We explored the relationship between plasma sclerostin levels and CVDs and bone phenotypes using Mendelian randomization (MR) and correlation between plasma sclerostin levels and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.